ERBB2 and breast carcinoma: In contrast, according to the current German AGO recommendation, the presence of a pCR, and thus also the axillary lymph node status in patients with hormone receptor-positive, HER2-negative breast cancer, does not influence the type of adjuvant systemic therapy [17].